I am reading the trial table rather than the press release, which is why the numbers differ.
I understand the observation; what I do not understand is the mechanism behind it.
I have read the two review articles that come up first and both assert this without a citation to a primary source.
What is actually going on here, physically?
Answering this needs to distinguish obstructive from central apnoea, because the mechanism and the expected response differ entirely.
SURMOUNT-OSA studied tirzepatide in adults with obesity and moderate-to-severe obstructive sleep apnoea, both with and without positive-airway-pressure therapy, and reported reductions in the apnoea–hypopnoea index of roughly twenty-five to thirty events per hour against a small placebo change.
| Quantity | Value | Derivation |
|---|---|---|
| Control-arm event rate | 8.0 % | From the trial table, not the abstract |
| Hazard ratio | 0.80 | Reported |
| Treated event rate | 6.4 % | 8.0 × 0.80 |
| Absolute risk reduction | 1.6 pp | 8.0 − 6.4 |
| Number needed to treat | 63 | 1 ÷ 0.016 |
| Relative risk reduction | 20 % | 1 − 0.80 |
The last two rows describe the same finding. Only one of them is used in headlines.
The correlation between weight change and AHI change in these trials is strong but not deterministic — craniofacial anatomy, muscle tone and sleep position all contribute, and none of them respond to weight loss.
Apnoea–hypopnoea index thresholds and the scoring rules for hypopnoea have changed more than once, so trials using different scoring criteria report systematically different numbers.
A two-band improvement is a real result and is not the same as resolution.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemStart with the severity band. Mild, moderate and severe obstructive sleep apnoea are defined by AHI thresholds, and moving between bands is the clinically meaningful change.
Home sleep apnoea tests systematically underestimate AHI relative to laboratory polysomnography, so a before-and-after comparison should use the same modality or the difference is partly instrumental.
Specifically, daytime somnolence scores improve alongside AHI in these trials, but they also improve with placebo, which is why the instrumented endpoint is the one that carries the argument.
Adherence to positive airway pressure is the main confounder in any real-world comparison and is rarely measured well outside a trial.
Cite the polysomnography endpoint, not the sleepiness questionnaire.
The relevant caution is that improvement is not resolution, and stopping established therapy on the strength of a symptom change is the error to avoid.
AHI bands are conventionally five to fifteen for mild, fifteen to thirty for moderate and above thirty for severe. A fall from forty-five to eighteen is a two-band move and still leaves moderate disease.
Positional dependence matters: an index averaged across the night conceals whether the events are concentrated supine, which changes what a partial improvement is worth.
The caveat is important here: an improved index is not a reason to discontinue prescribed therapy, and that decision needs a repeat sleep study and a clinician.
Get a baseline study before you need a comparison, because you cannot obtain one retrospectively.
The honest answer is that the effect is large in relative terms and that a large relative reduction from a severe baseline can still leave a treatable condition.
Central apnoeas are counted in the same index but arise from respiratory control rather than airway collapse, and there is no reason to expect a weight-mediated intervention to address them.
This is one of the few places where the instrumented evidence in this class is unusually clean. Use it.
edited 2 May 2025 by Dr_Ilse_Vandenberg — added the citation requested in comments
Answer first: the endpoint in this area is the apnoea–hypopnoea index, events per hour of sleep, measured by polysomnography. Symptom reports are not that endpoint and do not substitute for it.
Oxygen desaturation index and time below ninety per cent saturation are secondary measures that often move further than AHI, because they weight the severe events rather than counting all events equally.
SURMOUNT-OSA is the dedicated trial in this indication and used polysomnography rather than symptom scales, which is why its result is quotable.
Compare like with like: same modality, same scoring rules, or the difference is partly an artefact.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.